Psoriatic Arthritis Treatment Market - By Drug Type (NSAIDs, DMARDs [Synthetic, Biologics], Biological Agents [TNF, IL-17, IL-23]), Route of Administration, Medication Type, Age Group, Distribution Channel – Global Forecast (2024 – 2032)

Psoriatic Arthritis Treatment Market - By Drug Type (NSAIDs, DMARDs [Synthetic, Biologics], Biological Agents [TNF, IL-17, IL-23]), Route of Administration, Medication Type, Age Group, Distribution Channel – Global Forecast (2024 – 2032)

Global Psoriatic Arthritis Treatment Market size will expand at 9.7% CAGR from 2024 to 2032, due to the surging government and regulatory support. Ongoing initiatives are streamlining approval processes for new therapies and enhancing accessibility to existing treatments.

Numerous regulatory bodies are facilitating faster approvals and providing guidelines to ensure safe and effective treatment options for patients. Increased funding and supportive policies are further driving the development of advanced treatment options to foster research into novel approaches to enhance patient care, improve outcomes, and manage psoriatic arthritis (PsA) more effectively. For instance, in December 2023, UCB announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) had approved BIMZELX® (bimekizumab) for treating adults with PsA

The psoriatic arthritis treatment market is segregated into drug type, route of administration, medication type, age group, distribution channel, and region.

By age group, the 60 and above segment is estimated to rise at significant CAGR from 2024 to 2032, driven by increasing demand to address age-specific needs. Ongoing research is helping to explore how treatments can be tailored to manage symptoms effectively while considering potential age-related complications. Healthcare providers are also evaluating the efficacy and safety of existing therapies in older adults for ensuring that they align with the unique health profiles.

Psoriatic arthritis treatment industry share from the online pharmacies distribution channel segment is expected to witness robust growth from 2024 to 2032. This is owing to the rising obligation for providing a wider range of medications and specialized therapies through digital platforms for improving convenience for patients. These online services help to ensure timely delivery and proper storage of medications to maintain efficacy. The growing focus on improving patient engagement to provide more comprehensive and accessible treatment options for managing psoriatic arthritis effectively will drive the segment growth.

Regionally, the Europe psoriatic arthritis treatment industry size is forecasted to depict robust growth between 2024 and 2032, propelled by the increasing incidence of the condition and the rising prevalence of comorbidities. Ongoing efforts are refining treatment strategies to address both psoriatic arthritis and associated health issues effectively. Rapid advancements for enhancing patient outcomes by providing integrated care solutions to address both the primary condition and related health challenges will favor the regional market growth.